A 28-year-old woman with a 10-year history of progressive muscle weakness, myalgia, and recurrent rhabdomyolysis is found to have elevated plasma long-chain acylcarnitines, normal ammonia, and normal liver function. Muscle biopsy shows lipid storage myopathy. Genetic testing confirms very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. She is currently on a standard diet with no dietary restrictions. What is the most appropriate next step in management?

Explanation

## Clinical Context VLCAD deficiency is an autosomal recessive disorder affecting the oxidation of very-long-chain fatty acids (C12–C20). The adult-onset myopathic form presents with progressive muscle weakness, lipid storage, and recurrent rhabdomyolysis triggered by fasting, exercise, or infection. ## Pathophysiology of VLCAD Deficiency **Key Point:** VLCAD catalyzes the first dehydrogenation of very-long-chain acyl-CoA molecules. Enzyme deficiency causes: - Accumulation of very-long-chain acylcarnitines in plasma and muscle (diagnostic marker) - Impaired energy production from long-chain fatty acid oxidation - Lipid storage in muscle (lipid storage myopathy) - Recurrent rhabdomyolysis from energy crisis during catabolic stress - Preserved liver function (unlike LCHAD, which causes hepatic dysfunction) ## Management Strategy for VLCAD **High-Yield:** VLCAD is **carnitine-responsive** and **diet-modifiable**: ### 1. L-Carnitine Supplementation - **Mechanism:** VLCAD deficiency impairs the carnitine shuttle system; exogenous carnitine restores capacity for medium-chain and short-chain fatty acid oxidation - **Dosing:** 100–400 mg/kg/day (divided doses) - **Effect:** Reduces acylcarnitine accumulation and improves energy metabolism ### 2. Medium-Chain Triglyceride (MCT) Diet - **Rationale:** MCTs (C6–C10) bypass VLCAD and are oxidized by MCAD and SCAD, providing alternative energy source - **Implementation:** Replace 50–75% of dietary long-chain fat with MCT oil; avoid fasting - **Benefit:** Reduces lipid storage and rhabdomyolysis risk ### 3. Lifestyle Modifications - Avoid prolonged fasting - Prevent strenuous exercise without adequate carbohydrate intake - Manage infections promptly **Clinical Pearl:** Unlike MCAD (which does NOT respond to carnitine), VLCAD patients show dramatic clinical improvement with carnitine + MCT diet, often with normalization of acylcarnitine levels and reduction in muscle symptoms. ## Comparison: VLCAD vs. MCAD Management | Parameter | VLCAD | MCAD | | --- | --- | --- | | Carnitine responsive | Yes (100–400 mg/kg/day) | No | | Diet modification | MCT diet (reduce long-chain fat) | Frequent carbohydrate meals | | Acylcarnitine pattern | Very-long-chain ↑ | Medium-chain ↑ | | Liver involvement | Rare | Hepatomegaly common | | Muscle involvement | Lipid storage myopathy | Hypoketotic hypoglycemia | **Mnemonic:** **VLCAD = Very Long Chain, Carnitine, Avoid fasting, Diet (MCT)**